Shorts

Mapping Therapy-Driven Immune Changes in Metastatic PDAC

Is 2026 the Pivotal Year for Liquid Biopsies in Breast Cancer?

Overlaps in Breast and Gynecologic Cancer Treatments

The Future of Personalized Kidney Cancer Treatment

Predicting Melanoma Treatment Success After 3-4 Weeks

Intravesical Erdafitinib Evaluated in Phase 1 NMIBC Trial

Exploring Immune Data to Guide Pancreatic Cancer Immunotherapy

How MRD Could Fast-Track Cancer Breakthroughs

Why Bone Health Is Crucial in Prostate Cancer Treatment

Why PSMA PET Is the New Gold Standard for Prostate Cancer

Impressive Durability in New Cancer Combo Therapy

Dr Hoehn on a More Equitable Approach to Clinical Trials

A Breakthrough in Renal Cell Carcinoma Treatment

How ctDNA and Genomics Are Changing Modern Oncology

ctDNA: The Future of Detecting Cancer Recurrence

T-Cell Engagers Look Promising in Prostate Cancer

Turning “Negative” PDAC Trials Into Future Breakthroughs

The Flaw in Current Prostate Cancer Biomarkers

Understanding Bone Protective Agents

Test First, Treat Second: ASCO's Updated Approach to Driver Mutation–Negative NSCLC

The “Donut” Pattern of Clinical Trial Enrollment

Strategies for Anemia Management in Myelofibrosis

Financial Barriers Outweigh Race in Clinical Trial Enrollment

Managing Anemia and Transfusion Access Challenges

Predicting Cancer Outcomes with ctDNA Status in Bladder Cancer

PIM Inhibitor Shows Promise in High-Risk Myelofibrosis

More Than a Marker: Behind the Aggressive Nature of CD25+ Leukemias

What’s Needed to Bring Clinical Trials to the Patient

Can GLP-1 Agonists Help Treat Rare Cancers?

Initial Assessments in Metastatic RCC